ReviewPharmaceuticals (Basel, Switzerland)2023

Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease.

Janae Gonzales et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.